The clinical community is closely watching this groundbreaking treatment, a dual-action drug targeting both the incretin pathway and another key signal. Initial data suggest it could offer substantial improvements in reducing body weight compared to existing approaches, potentially representing a significant step forward in the battle of excess … Read More